Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

Biotechnology

Healthcare
$33.11 -1.81%

-$0.61 today

Market cap
$1.94B
Beta
0.97
P/E (TTM)
13.2
EPS (TTM)
$2.52
52W Low $25.52High $40.87

Volume 0.57M

Average 0.82M

HRMY EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Harmony Biosciences Holdings, Inc.NASDAQ: HRMY

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA growth accelerates

Q2 FY2026 EBITDA of $102.3M rose 72.7% year over year, ahead of the +4.3% change in trailing-twelve-month EBITDA. Sequentially, it rose 109.3% from the prior quarter. Over 3 fiscal years it compounded at +20.2% a year.

Context

  • EBITDA amounted to 29.4% of revenue in FY2025, down 3.3 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 9 analysts of $289.73M (+13.6%) for the fiscal year ending Dec 2026, a step up from the +9.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$102.3M+109.3% QoQ
Last fiscal yearDec 2025
$255.05M+9.3% YoY
LTMJun 2026
$276.39M+4.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+72.7%+18.4%-54.3 pp
1 year+9.3%+13.6%+4.3 pp
3-year CAGR+20.2%+15.8%-4.4 pp
5-year CAGR+9.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
255.05M USD
Year-over-year change
+9.3%
4-year CAGR
+33.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How HRMY compares with its peers on the latest reported figures

  • HRMY's LTM Jun 2026 EBITDA of $276.39M is the highest of the 4 companies compared; the peer median is -$176.6M.
  • Its year-over-year change of +4.3% is the highest of 3, against a peer median of -1821.5%.
  • EBITDA amounts to 28.8% of revenue for HRMY.
HRMY Competitors Peer median
EBITDA for HRMY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 2026$276.39M +4.3%+20.2%28.8%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026-$39.05M ———
CMPSCOMPASS Pathways plcLTM Mar 2026-$176.6M -34.4%——
NERVMinerva Neurosciences, Inc.LTM Jun 2026-$394.35M -3608.6%——
APMDApnimed, Inc.—— ———
Peer median (excluding HRMY) -$176.6M-1821.5%——

Competitors are the stored peer set for HRMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue305.44M437.86M582.02M714.73M868.45M
Cost of Revenue55.52M83.48M121.24M156.82M198.34M
Gross Profit249.92M354.37M460.79M557.92M670.11M
Gross Margin81.8%80.9%79.2%78.1%77.2%
Research & Development30.37M70.89M76.06M145.83M189.59M
Selling, General & Admin132.03M163.3M192.69M221.27M272.05M
Operating Expenses162.39M234.19M268.76M367.09M461.64M
Depreciation & Amortization18.84M23.39M24.36M24.11M25.34M
EBITDA80.46M146.87M221.51M233.41M255.05M
EBITDA Margin26.3%33.5%38.1%32.7%29.4%
Operating Income87.53M120.19M192.03M190.83M208.47M
Operating Margin28.7%27.4%33.0%26.7%24.0%
Interest Income224K3.13M14.73M18.54M21.92M
Interest Expense24.19M18.8M23.76M17.5M14.65M
Other Income / Expenses(50.1M)(15.5M)(18.63M)978K6.6M
Income Before Tax37.43M104.69M173.4M191.8M215.06M
Pre-Tax Margin12.3%23.9%29.8%26.8%24.8%
Income Tax Expense2.83M(76.78M)44.54M46.31M56.38M
Net Income34.6M181.47M128.85M145.49M158.69M
Net Margin11.3%41.4%22.1%20.4%18.3%
EPS (Basic)0.603.072.172.562.76
EPS (Diluted)0.582.972.132.512.71
Weighted Avg Shares57.53M59.17M59.47M56.89M57.49M
Weighted Avg Shares (Diluted)59.21M61.1M60.37M57.87M58.54M

Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

Intrinsic Alpha fair value

Locked

Current Price

$33.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.